Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Cyclopentanohydrophenanthrene ring system doai
Reexamination Certificate
2006-02-07
2006-02-07
Weddington, Kevin E. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Cyclopentanohydrophenanthrene ring system doai
Reexamination Certificate
active
06995150
ABSTRACT:
Androst-5-ene-3β,17β diol is used to treat or reduce the likelihood of acquiring osteoporosis or menopausal symptoms, or other diseases affected by estrogen receptor activity, and for conditions which respond well to DHEA treatment, but where a higher ratio of estrogenic to androgenic effects is desired. Combination therapies are included, as are kits and pharmaceutical compositions or providing the active ingredients of claimed methods and combinations.
REFERENCES:
patent: 3742951 (1973-07-01), Zaffaroni
patent: 3797444 (1974-03-01), Stubbs
patent: 4064654 (1977-12-01), Olson
patent: 4162037 (1979-07-01), Koyama
patent: 4568343 (1986-02-01), Leeper et al.
patent: 4624665 (1986-11-01), Nuwayser
patent: 4634694 (1987-01-01), Loozen et al.
patent: 4666441 (1987-05-01), Andriola et al.
patent: 5071644 (1991-12-01), Viegas et al.
patent: 5071657 (1991-12-01), Oloff et al.
patent: 5116828 (1992-05-01), Miura et al.
patent: 5135480 (1992-08-01), Bannon et al.
patent: 5154922 (1992-10-01), Govil et al.
patent: 5183815 (1993-02-01), Saari et al.
patent: 5206008 (1993-04-01), Loria
patent: 5387583 (1995-02-01), Loria
patent: 5461042 (1995-10-01), Loria
patent: 5641768 (1997-06-01), Loria
patent: 5728688 (1998-03-01), Labrie
patent: 5798347 (1998-08-01), Labrie
patent: 5807849 (1998-09-01), Labrie
patent: 5837700 (1998-11-01), Labrie
patent: 5843932 (1998-12-01), Labrie
patent: 5922700 (1999-07-01), Labrie
patent: 6432940 (2002-08-01), Labrie
patent: 0279982 (1987-11-01), None
patent: 0424954 (1991-05-01), None
patent: 816689 (1961-07-01), None
patent: 2185187 (1986-06-01), None
patent: 192286 (1986-01-01), None
patent: 03-209328 (1991-09-01), None
patent: 8-505629 (1996-06-01), None
patent: 3361523 (2002-10-01), None
patent: 9316704 (1993-09-01), None
patent: WO 93/20696 (1993-10-01), None
patent: 9416709 (1994-08-01), None
patent: 9703676 (1997-02-01), None
patent: 98/56386 (1998-12-01), None
Hungarian Novelty Search Report of Application No. P01 02483 dated Oct. 14, 2002.
Printout list of patent family for U.S. Patent 4,634,694 (Hungarian Patent No. 192286B).
Bird, et al., Acta Endo., 99(2):309-313 (1982).
Dauvois, et al., Breast Cancer Res., 13(1):61-69 (1989).
Tourniare, CAH. Med., 15(9):583-588 (1974).
Araneo, et al., J. Surg. Res., 59(2):250-262 (1995).
Kuiper, et al., Frontiers In ndo., 19(4):253-286 (1998).
Dorgan, et al., Cancer Epid., Biomarkers and Prev., 6(3):177-81 (1997).
Yoshimoto, et al., Horumon to Rinsho, Clin. Endo., 31(8):815-22 (1983).
Simard, et al., J. Steroid Biochem., 26(5):539-546 (1987).
Drugu 49784 Dunn, et al., abstract (1996).
Embase AN 95163258, Krause, abstract (1995).
Dunn, et al., Arch. Derm., 133(3):339-42, abstract (1996).
Couillard, et al., Maturitas, 27:80 (1997).
Luo, et al., Endocrinology, 138(10):4435-4444 (1997).
Pasqualini, J. Steroid Biochem. and Molecular Biology, 45(1-3):167-172 (1993).
Boccuzzi, et al., Anticancer Res., 13(6a)2267-2272 (1993).
Dowsett, et al., J. Clinical Endo. and Metab., 66(4)672-677 (1988).
Meyskens, Cancer Invest., 6(5):609-614 (1988).
Kreitmann & Bayard, J. Steroid Biochem., 11:1589-1595 (1979).
Adams, et al., Cancer Res., 41:4720-4926 (1981).
Furlanetto, et al., J. Clin. Invest., 60:648 (1977).
Korenman, “Sexual Dysfunctions”, Williams Textbook of Endo., pp. 1033-1048 (1992).
Nestler, et al., J. Clin. Endo. Metab., 66:57-61 (1988).
Masters, et al., J. Natl. Cancer Inst., 58:1263-1265 (1977).
Anderson, et al., Brit. J. Cancer, 46:376-382 (1982).
Potten, et al., Brit. J. Cancer, 58:163-170 (1988).
Going, et al., Am. J. Pathol., 130:193-204 (1988).
Ferland, et al., Hypothalamus and Endocrine Functions, pp. 191-209 (1976).
Romieu, et al., Cancer, 66:2253-2263 (1990).
Koller, et al., STP Pharma 3(2):115-124 (1987).
Belanger, et al., Clinical and Invest. Med., 11(5):321-326 (1988).
Pelletier, et al., J. Mol. Endocr., 1:213-223 (1988).
Rodbard, et al., Karolinska Symposia, Steroid Assay by Protein Binding, Mar. 23-25, 1970.
Poulin and Labrie, Cancer Res., 46:4933-4937 (1986).
Tindall, Walter J., Preparations for cosmetic and therapeutic treatment of the skin, NL 88000180 May 16, 1958 (copy of abstract).
Herbert J. Buschbaum, The Menopause, Springer-Verlag, New York, (1983) pp. 22-33 and pp. 73-84.
Abstract: Luo, et al., Effects of Combination of Dehydroepian-Drosterone and EM-800 on Bone Mass, Serum Lipids, and The Development of Dimethylbenz (A) Anthracene (DMBA)-Induced Mammary Carcinoma in the Rat, Breast Cancer Research & Treatment (1997) (vol. 46, No. 1).
Steeve Couillard, et al.. Effect of Dehydroepiandrosterone and The Antiestrogen EM-800 on Growth of Human ZR-75-1 Breast Cancer Xenografts, Jou. of the Natl. Cancer Inst. (1998) vol. 90, No. 10.
Hackenberg, R., et al., “Estrogen and androgen receptor mediated stimulation and inhibition of proliferation by androst-5-ene-3beta, 17 beta-diol in human mammary in cancer cells”,J. Steroid Biochem Mol Biol,1993 Nov; 46(5): 597-603.
Boccuzzi G., et al., “5-ene-androsterone-3beta, 17beta-diol inhibits the growth of MCF-7 breast cancer cells when estrogen receptors are blocked by estradiol”,Br J Cancer,1994 Dec; 70(6):1035-9.
Boccuzzi G., et al., “Influence of dehydroepiandrosterone and 5-ene-androsterone-3beta, 17beta-diol on the growth of MCF-7 human breast cancer cells induced by 17-beta-estradiol”Anticancer Res,1992 May-Jun; 12(3):799-803.
Communication from the European Office Action dated Jun. 22, 2004.
M. Shiraki, et al.; “The Effect of Estorgen and sex steroids and thyroid hormone preparation on bone mineral density in senile osteoporosis --a comparative study of the effect of 1 alpha-hydroxycholecalciferol (1 alpha-OHD3) on senile osteoporosis”, MEDLINE abstract of Nippon Naibunpi Gakkai Zasshi, vol. 67, No. 2, pp. 84-95, Feb. 20, 1991.
Fernand Labrie, et al.: “Interactions between Estrogens, Androgens, Progestins, and Glucocorticoids in ZR-75-1 Human Breast Cancer Cells,”, ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, New York Academy of Sciences, New York, NY, 199, vol. 585, pp. 130-148, XP-000852949.
Japanese Office Action dated Apr. 9, 2004 and translation.
Endorecherche Inc.
Ostrolenk Faber Gerb & Soffen, LLP
Weddington Kevin E.
LandOfFree
Pharmaceutical compositions and uses for... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical compositions and uses for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical compositions and uses for... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3649552